Orion Diagnostica proposes co-operation negotiations on streamlining its operations and reducing no more than 80 employees in Finland
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 10 APRIL 2013 at 08.55 EEST
Orion Diagnostica Oy, a subsidiary of Orion Corporation focusing on diagnostic
tests, has today given a negotiation proposal, as laid down in the Finnish Act
on Co-operation within Undertakings, on streamlining operations, reorganizing
production and possible personnel reductions. The estimate on the reduction need
is no more than 80 employees. The measures considered by the employer aim to
streamline operations and improve the company's profitability among other things
by simplifying the product portfolio. With the considered measures Orion
Diagnostica aims to ensure the continuity of operations and competitiveness also
in the future.
The negotiations concern all Orion Diagnostica's personnel, except some minor
exclusions, in all personnel groups in all sites in Finland. In addition to
other measures, the employer is considering closing down Orion Diagnostica's
Turku site. Possible reorganization of the operations is estimated to cause
changes in roles and responsibilities, lead to transfers of employees to other
positions or other sites, changes to the terms of employment as well as possible
terminations of employment by notice. Should redundancies occur, the employer
would, according to a preliminary estimate, give notice during 2013.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Timo Lappalainen, President and CEO
tel. +358 10 426 3692
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1691790]
Unternehmensinformation / Kurzprofil:
Datum: 10.04.2013 - 07:55 Uhr
Sprache: Deutsch
News-ID 247581
Anzahl Zeichen: 3134
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Orion Diagnostica proposes co-operation negotiations on streamlining its operations and reducing no more than 80 employees in Finland"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
